This article has multiple issues. Please help improve it or discuss these issues on the talk page . (Learn how and when to remove these template messages)
|
Kevin Strange is an American medical researcher who is the former president and first full-time director of the MDI Biological Laboratory. He took the role in July 2009, after working as an NIH-funded biomedical scientist and academic leader at Harvard Medical School and Vanderbilt University School of Medicine. As President, Strange worked towards refocusing the MDI Biological Laboratory's research program and recruiting multidisciplinary scientists to understand the genetic mechanisms of tissue repair, regeneration, and aging. In 2013, three years after establishing this new research focus, the MDI Biological Laboratory was recognized by the National Institutes of Health as a center of research excellence in regenerative and aging biology and medicine. [1]
Strange was an Associate Professor at Harvard Medical School and Director of the critical care research laboratories at Children's Hospital in Boston. In 1997, he moved to Vanderbilt University School of Medicine, where he was the John C. Parker Professor and director of research in the department of anesthesiology. [1]
Strange is an expert in the field of cellular stress biology. His research focuses on how proteins are damaged by environmental stressors, how cells detect, degrade, and repair these damaged proteins and how cells protect themselves from osmotic stress. This work furthers the understanding of degenerative changes that occur as humans age. Strange has published over 125 original papers, review articles, and books. His laboratory has been funded continuously by the NIH and private foundations for over 30 years. He holds bachelor's and master's degrees from the University of California at Davis and received his doctorate from the University of British Columbia. [1]
In 2013, Strange founded the MDI Biological Laboratory's first spinout company, Revidia Therapeutics, Inc., to accelerate the testing and development of a novel drug candidate for patients with heart disease. [2] That year, the magazine Mainebiz named Strange one of Maine's ten most “innovative business people” who “hold tremendous promise for the state” and its future economy. [3]
Strange stepped down as president of MDI Biological Laboratory at the end of his second term in 2018 to focus his efforts on growing Revidia Therapeutics and advancing their drug candidate into clinical trials. Strange is currently Principal Scientist at Revidia Therapeutics and Professor of Anesthesiology at Vanderbilt University School of Medicine. [4]
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of the institutes and centers that make up the National Institutes of Health, an agency of the United States Department of Health and Human Services (HHS).
The University of Texas Southwestern Medical Center is a public academic health science center in Dallas, Texas. With approximately 23,000 employees, more than 3,000 full-time faculty, and nearly 4 million outpatient visits per year, UT Southwestern is the largest medical school in the University of Texas System and the State of Texas.
The Kolling Institute is located in the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
The Cambridge Biomedical Campus is the largest centre of medical research and health science in Europe. The site is located at the southern end of Hills Road in Cambridge, England.
Russ Biagio Altman is an American professor of bioengineering, genetics, medicine, and biomedical data science and past chairman of the bioengineering department at Stanford University.
Jeremy Mark Berg was founding director of the University of Pittsburgh's Institute for Personalized Medicine. He holds positions as Associate Senior Vice Chancellor for Science Strategy and Planning and Professor of Computational and Systems Biology at the University of Pittsburgh. From 2016 to 2019, Berg was editor in chief of the Science journals.
Vanderbilt University School of Medicine (VUSM) is the graduate medical school of Vanderbilt University, a private research university located in Nashville, Tennessee. The School of Medicine is primarily housed within the Eskind Biomedical Library which sits at the intersection of the Vanderbilt University and Vanderbilt University Medical Center (VUMC) campuses and claims several Nobel laureates in the field of medicine. Through the Vanderbilt Health Affiliated Network, VUSM is affiliated with over 60 hospitals and 5,000 clinicians across Tennessee and five neighboring states which manage more than 2 million patient visits each year. As the home hospital of the medical school, VUMC is considered one of the largest academic medical centers in the United States and is the primary resource for specialty and primary care in hundreds of adult and pediatric specialties for patients throughout the Mid-South.
Kelvin J. A. Davies is the James E. Birren Chair of Gerontology at the USC Davis School of Gerontology with a joint appointment in Dana and David Dornsife College of Letters, Arts and Sciences in biology. He is involved in researching free radical biology, oxidative stress, and aging; and was an early member of the study of protein oxidation, proteolysis, and altered gene expression during stress-adaptation; he also found the role of free radicals in mitochondrial adaptation to exercise, and demonstrated the role of diminished oxidative stress-adaptive gene expression in aging.
Jeffrey R. Balser is the president and CEO of Vanderbilt University Medical Center (VUMC) and dean of the Vanderbilt University School of Medicine (VUSM). Balser is a 1990 graduate of the Vanderbilt M.D./Ph.D. program in pharmacology and subsequently completed residency training in anesthesiology and fellowship training in critical care medicine at Johns Hopkins. He continued to work at Johns Hopkins as a cardiac anesthesiologist and ICU physician before returning to Vanderbilt University and joining VUMC in 1998. Balser was appointed dean of the VUSM in 2008 and, the following year, was appointed the vice chancellor for health affairs at Vanderbilt, in charge of the medical center. He became president and CEO of VUMC in 2016 when the medical center became a financially distinct non-profit organization.
Translational research is research aimed at translating (converting) results in basic research into results that directly benefit humans. The term is used in science and technology, especially in biology and medical science. As such, translational research forms a subset of applied research.
The MDI Biological Laboratory (MDIBL), formerly known as Mount Desert Island Biological Laboratory is an independent non-profit biomedical research institution founded in 1898 and located in Salisbury Cove, Maine, on Mount Desert Island. Its mission is to improve human health and well- being through basic research, education, and development ventures that transform discoveries into cures. In 2013, the Laboratory was designated a Center for Biomedical Research Excellence (COBRE) by the National Institutes of Health, which awarded the Laboratory a grant of $13 million over five years to expand the institution’s research program. The MDI Biological Laboratory has a full-time staff of 63, and will offer 23 research training courses in 2014.
Ronald David Vale ForMemRS is an American biochemist and cell biologist. He is a professor at the Department of Cellular and Molecular Pharmacology, University of California, San Francisco. His research is focused on motor proteins, particularly kinesin and dynein. He was awarded the Canada Gairdner International Award for Biomedical Research in 2019, the Shaw Prize in Life Science and Medicine in 2017 together with Ian Gibbons, and the Albert Lasker Award for Basic Medical Research in 2012 alongside Michael Sheetz and James Spudich. He is a fellow of the American Academy of Arts and Sciences and a member of the National Academy of Sciences. He was the president of the American Society for Cell Biology in 2012. He has also been an investigator at the Howard Hughes Medical Institute since 1995. In 2019, Vale was named executive director of the Janelia Research Campus and a vice president of HHMI; his appointment began in early 2020.
Amy J. Wagers is the Forst Family Professor of Stem Cell and Regenerative Biology at Harvard University and Harvard Medical School, an investigator in islet cell and regenerative biology at the Joslin Diabetes Center, and principal faculty of the Harvard Stem Cell Institute. She is co-chair of the Department of Stem Cells and Regenerative Biology at Harvard Medical School.
Susan Wente is an American cell biologist and academic administrator currently serving as the 14th and current President of Wake Forest University. From 2014 to 2021 she was Provost and Vice Chancellor for Academic Affairs at Vanderbilt University. Between August 15, 2019 and June 30, 2020, she served as interim Chancellor at Vanderbilt.
Nathanael S. Gray is an American chemist. He serves as Krishnan-Shah Family Professor of chemical and systems biology at Stanford University and director of cancer therapeutics programme at Stanford University School of Medicine. Previously he was a Nancy Lurie Marks Professor of biological chemistry and molecular pharmacology at Harvard Medical School and professor of cancer biology at Dana–Farber Cancer Institute. Gray is also co-founder, science advisory board member (SAB) and equity holder in C4 Therapeutics, Gatekeeper, Syros, Petra, B2S, Aduro, Jengu, Allorion, Inception Therapeutics, and Soltego. C4 Therapeutics, which offered IPO in 2020, was founded based on the ground-breaking research of Jay Bradner, current president of Novartis Institutes for BioMedical Research (NIBR), and of Nathanael S. Gray, while he was professor at Harvard Medical School. Before moving to Stanford University, Nathanael S. Gray created Center for Protein Degradation at Harvard Medical School with $80 million agreement with Deerfield Management venture capital firm. In 2020, Gray Lab permanently moved to Stanford University, that was stated by Stuart Schreiber, co-founder of Broad Institute as "Stanford's huge gain".
Gregory L. Verdine is an American chemical biologist, biotech entrepreneur, venture capitalist and university professor. He is a founder of the field of chemical biology, which deals with the application of chemical techniques to biological systems. His work has focused on mechanisms of DNA repair and cell penetrability.
William Allen Eaton is a biophysical chemist who is a NIH Distinguished Investigator, Chief of the Section on Biophysical Chemistry, and Chief of the Laboratory of Chemical Physics at the National Institute of Diabetes and Digestive and Kidney Diseases, one of the 20 Institutes of the United States National Institutes of Health.
Barney S. Graham is an American immunologist, virologist, and clinical trials physician.
Lee Limbird is a pharmacologist, Dean of the School of Natural Science, Mathematics and Business & Professor in the Department of Life and Physical Sciences at Fisk University, Nashville, Tennessee.
Fabrisia Ambrosio is a Brazilian-born physical therapist and researcher. She is the Director of Rehabilitation for UPMC International and an associate professor in the Department of Physical Medicine & Rehabilitation at the University of Pittsburgh. Her research focuses on developing regenerative technologies to prevent or reverse the effect of age and/or environmental exposures on stem cell and tissue function. In 2022, Ambrosio was elected a Fellow of the American Institute for Medical and Biological Engineering for "outstanding contributions to the novel field of Regenerative Rehabilitation, integrating applied biophysics and cellular therapeutics to optimize tissue function."